{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:47:24Z","timestamp":1788824844912,"version":"build-2803163510"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Egypt has the highest prevalence of hepatitis C virus (HCV) in the world thus it launched a national program for eliminating HCV aiming to treat 300,000 HCV patients per year. Three anti-HCV co-administered drugs; ribavirin (RBV), sofosbuvir (SF) daclatasvir (DAC) were simultaneously determined in human plasma by a validated, simple and sensitive RP-HPLC method using propyl paraben as an internal standard. Liquid\u2013liquid extraction using ethyl acetate was used for samples extraction. Chromatographic separation was achieved on Scharlau\u00ae C18 column (250 \u00d7 4.6 mm2, 5 \u03bcm). Gradient elution was employed with a mobile phase mixture of water and acetonitrile at a flow rate 1 mL\/min. UV detection using photodiode array detector was carried out at 207, 260 and 312 nm for RBV, SF and DAC, respectively. Method validation was performed according to the FDA guidelines for bioanalytical method validation. The calibration curves were linear over the ranges (0.5\u201380, 0.1\u201340 and 0.5\u201380 \u03bcg\/mL) with average recoveries (100.64\u2013108.28%, 98.48\u2013105.91% and 97.68\u2013101.38%) for RBV, SF and DAC, respectively. The intra-day and inter-day precision and accuracy results were within the acceptable limits. Stability assays revealed that the three studied analytes were stable during sample storage, preparation and injection. The method can be successfully applied in routine analysis of plasma of HCV patients treated with this combination therapy which aids in therapeutic drug monitoring and patients\u2019 follow-up especially in Egypt and other developing countries fighting HCV.<\/jats:p>","DOI":"10.1093\/chromsci\/bmz038","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T15:13:57Z","timestamp":1554477237000},"page":"636-643","source":"Crossref","is-referenced-by-count":19,"title":["Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt"],"prefix":"10.1093","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0718-8785","authenticated-orcid":false,"given":"Aya A","family":"Youssef","sequence":"first","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Magdy","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna A","family":"Hussein","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"El-Kosasy","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Organization of African Unity Street, Abassia, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"2019072703201425000_bmz038C1","author":"WHO prevalence HCV","year":"2019"},{"issue":"11","key":"2019072703201425000_bmz038C2","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.3390\/v7112898","article-title":"Host-targeting agents to prevent and cure hepatitis C virus infection","volume":"7","author":"Zeisel","year":"2015","journal-title":"Viruses"},{"key":"2019072703201425000_bmz038C3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17936-4","article-title":"Virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions","volume":"8","author":"Kouyoumjian","year":"2018","journal-title":"Scientific Reports"},{"key":"2019072703201425000_bmz038C4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/HMER.S113681","article-title":"Hepatitis C infection in Egypt: prevalence, impact and management strategies","volume":"9","author":"Gomaa","year":"2017","journal-title":"Hepatic Medicine: Evidence and Research"},{"key":"2019072703201425000_bmz038C5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment","volume":"37","author":"Kandeel","year":"2017","journal-title":"Liver International : Official Journal of the International Association for the Study of the Liver"},{"key":"2019072703201425000_bmz038C6","author":"Egypt","year":"2018"},{"key":"2019072703201425000_bmz038C7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jchromb.2015.11.056","article-title":"Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC\u2013MS\/MS and its application to a pharmacokinetic study","volume":"1008","author":"Pan","year":"2016","journal-title":"Journal of Chromatography B"},{"issue":"11","key":"2019072703201425000_bmz038C8","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.43.11.2716","article-title":"High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes","volume":"43","author":"Homma","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"2019072703201425000_bmz038C9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/cir774","article-title":"Boceprevir and telaprevir in the management of hepatitis C virus-infected patients","volume":"54","author":"Butt","year":"2012","journal-title":"Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America"},{"key":"2019072703201425000_bmz038C10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/HMER.S62014","article-title":"Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C Virus infection: from the clinical trials to real life","volume":"8","author":"Pol","year":"2016","journal-title":"Hepatic Medicine: Evidence and Research"},{"issue":"4","key":"2019072703201425000_bmz038C11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12072-018-9861-2","article-title":"Sofosbuvir plus daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience","volume":"12","author":"Shiha","year":"2018","journal-title":"Hepatology International"},{"issue":"2","key":"2019072703201425000_bmz038C12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpba.2007.06.004","article-title":"Ribavirin: analytical determinations since the origin until today","volume":"45","author":"Bosch","year":"2007","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"8","key":"2019072703201425000_bmz038C13","first-page":"607","article-title":"Analytical method development and validation of ribavirin in pharmaceutical dosage form by Rp-Hplc method","volume":"4","author":"Mahaparale","year":"2017","journal-title":"The European Journal Plarmaceutical Medical Research"},{"issue":"4","key":"2019072703201425000_bmz038C14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/chromsci\/bmu092","article-title":"Validated stability-indicating liquid chromatographic method for the determination of ribavirin in the presence of its degradation products: application to degradation kinetics","volume":"53","author":"Belal","year":"2015","journal-title":"Journal of Chromatographic Science"},{"issue":"10","key":"2019072703201425000_bmz038C15","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1128\/AAC.48.10.3813-3816.2004","article-title":"Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood","volume":"48","author":"Inoue","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"2019072703201425000_bmz038C16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpba.2004.12.006","article-title":"A sensitive and specific method for the determination of total ribavirin in monkey liver by high-performance liquid chromatography with tandem mass spectrometry","volume":"38","author":"Yeh","year":"2005","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2019072703201425000_bmz038C17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpba.2013.11.027","article-title":"Development and validation of a useful UPLC-MS\/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients","volume":"90","author":"Agnesod","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"3","key":"2019072703201425000_bmz038C18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0731-7085(02)00003-1","article-title":"Development and validation of a liquid chromatography\/tandem mass spectrometry (LC\/MS\/MS) method for the determination of ribavirin in human plasma and serum","volume":"29","author":"Shou","year":"2002","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"1\u20132","key":"2019072703201425000_bmz038C19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2006.03.019","article-title":"Validation of liquid\/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients","volume":"835","author":"D\u2019Avolio","year":"2006","journal-title":"Journal of Chromatography B"},{"issue":"2","key":"2019072703201425000_bmz038C20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1570-0232(02)00379-3","article-title":"Specific, sensitive and accurate liquid chromatographic-tandem mass spectrometric method for the measurement of ribavirin in rat and monkey plasma","volume":"779","author":"Lin","year":"2002","journal-title":"Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences"},{"issue":"1","key":"2019072703201425000_bmz038C21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.47.1.124-129.2003","article-title":"Ribavirin quantification in combination treatment of chronic hepatitis C","volume":"47","author":"Larrat","year":"2003","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"2019072703201425000_bmz038C22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpba.2012.03.030","article-title":"Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients","volume":"66","author":"D\u2019Avolio","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"6","key":"2019072703201425000_bmz038C23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/chromsci\/bmt067","article-title":"Stability-indicating HPLC-DAD determination of ribavirin in capsules and plasma","volume":"52","author":"Haggag","year":"2014","journal-title":"Journal of Chromatographic Science"},{"key":"2019072703201425000_bmz038C24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chroma.2012.05.028","article-title":"A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (Daclastasvir) in human plasma and urine","volume":"1245","author":"Jiang","year":"2012","journal-title":"Journal of Chromatography A"},{"issue":"7","key":"2019072703201425000_bmz038C25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10337-017-3321-3","article-title":"Reversed-phase liquid chromatographic method for determination of daclatasvir dihydrochloride and study of its degradation behavior","volume":"80","author":"Hassib","year":"2017","journal-title":"Chromatographia"},{"key":"2019072703201425000_bmz038C26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC-MS\/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"12","key":"2019072703201425000_bmz038C27","first-page":"1565","article-title":"Stability indicating HPLC method development and validation for determination of daclatasvir in pure and tablets dosage forms","volume":"3","author":"Saleh","year":"2016","journal-title":"INDO American Journal of Pharmaceutical Scienes"},{"issue":"8","key":"2019072703201425000_bmz038C28","first-page":"107","article-title":"Development and validation of stability indicating RP-HPLC method for the estimation of daclatasvir in bulk and formulation","volume":"15","author":"Sumathi","year":"2016","journal-title":"Der Pharmazie Letters"},{"issue":"7","key":"2019072703201425000_bmz038C29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"2019072703201425000_bmz038C30","first-page":"392","article-title":"Simultaneous RP-HPLC method development and it\u2019s validation for estimation of sofosbuvir and velpatasvir in their combined dosage form","volume":"11","author":"Mamatha","year":"2018","journal-title":"RASAYAN Journal Chemistry"},{"issue":"2","key":"2019072703201425000_bmz038C31","first-page":"121","article-title":"Estimation and validation of sofosbuvir in bulk and tablet dosage form by Rp-Hplc","volume":"6","author":"Vejendla","year":"2016","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"2019072703201425000_bmz038C32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5155\/eurjchem.7.3.375-379.1439","article-title":"Simple chromatographic and spectrophotometric determination of sofosbuvir in pure and tablet forms","volume":"7","author":"Abdel-Gawad","year":"2016","journal-title":"European Journal Chemistry"},{"issue":"5","key":"2019072703201425000_bmz038C33","first-page":"775","article-title":"Development and validation of new Rp-Hplc method for the determination of sofosbuvir in pure form","volume":"5","author":"Vikas","year":"2016","journal-title":"World Journal Pharmacology Pharmaceutical Science"},{"issue":"4","key":"2019072703201425000_bmz038C34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jpha.2017.04.003","article-title":"Potential of RP-UHPLC-DAD-MS for the qualitative and quantitative analysis of sofosbuvir in film coated tablets and profiling degradants","volume":"7","author":"Contreras","year":"2017","journal-title":"Journal of Pharmaceutical Analysis"},{"issue":"9","key":"2019072703201425000_bmz038C35","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bmc.3690","article-title":"Novel and sensitive UPLC\u2013MS\/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study","volume":"30","author":"Rezk","year":"2016","journal-title":"Biomedical Chromatography: BMC"},{"key":"2019072703201425000_bmz038C36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2015.05.006","article-title":"Development of a sensitive UPLC-ESI-MS\/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study","volume":"114","author":"Rezk","year":"2015","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"5","key":"2019072703201425000_bmz038C37","first-page":"60","article-title":"Development and validation of a new, simple-HPLC method for simultaneous determination of sofosbuvir, daclatasvir and ribavirin in tablet dosage form","volume":"12","author":"Wadie","year":"2017","journal-title":"IOSR Journal Pharmaceutica Biological Sciences"},{"key":"2019072703201425000_bmz038C38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2015.08.038","article-title":"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS\/MS","volume":"1002","author":"Shi","year":"2015","journal-title":"Journal Chromatography B"},{"issue":"1","key":"2019072703201425000_bmz038C39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.26502\/jppr.0004","article-title":"The development of a new validated HPLC and spectrophotometric methods for the simultaneous determination of daclatasvir and sofosbuvir: antiviral drugs","volume":"1","author":"Eldin","year":"2017","journal-title":"Journal Pharmacy and Pharmacology Research"},{"key":"2019072703201425000_bmz038C40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bmc.4186","article-title":"Development and validation of LC-MS\/MS method for simultaneous determination of sofosbuvir and daclatasvir in human plasma: application to pharmacokinetic study","volume":"32","author":"Abdallah","year":"2018","journal-title":"Biomedical Chromatography : BMC"},{"key":"2019072703201425000_bmz038C41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/gs-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2019072703201425000_bmz038C42","author":"US Food and Drug Administration","year":"2018"},{"issue":"1","key":"2019072703201425000_bmz038C43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4155\/bio.13.298","article-title":"NewUS. FDA draft guidance on bioanalyticalmethod validation versus current FDA and EMA Guidelines: chromatographic methods and ISR","volume":"6","author":"Zimmer","year":"2014","journal-title":"Bioanalysis"},{"issue":"3","key":"2019072703201425000_bmz038C44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/apt.14428","article-title":"Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt","volume":"47","author":"Omar","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"2019072703201425000_bmz038C45","author":"REBETRON","year":"2019"},{"issue":"5","key":"2019072703201425000_bmz038C46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40265-015-0362-5","article-title":"Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/chromsci\/advance-article-pdf\/doi\/10.1093\/chromsci\/bmz038\/28565531\/bmz038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/57\/7\/636\/29008930\/bmz038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T03:20:35Z","timestamp":1564197635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/57\/7\/636\/5486447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,5,7]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmz038","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,7]]}}}